<Summary id="CDR0000799419" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>This evidence-based, expert-reviewed childhood cardiac tumors summary discusses histology, risk factors, clinical presentation, diagnostic evaluation, and treatment.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/cardiac/hp-child-cardiac-treatment-pdq">Childhood Cardiac Tumors (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/cardiac/patient-child-cardiac-treatment-pdq">Childhood Cardiac Tumors (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028557">PDQ Pediatric Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000038073">unusual cancers of childhood</TermRef></MainTopics><SummaryAbstract><Para id="_1556">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood cardiac tumors. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_1557">This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>Cardiac tumors</SummaryKeyWord><SummaryKeyWord>Pediatric cardiac cancer</SummaryKeyWord><SummaryKeyWord>Pediatric heart cancer</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Childhood Cardiac Tumors Treatment (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Childhood Cardiac Tumors Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Childhood Cardiac Tumors Treatment</AltTitle><SummarySection id="_1063"><Title>Incidence and Types of Childhood Cardiac Tumors</Title><Para id="_1064">Cardiac tumors are rare in children, with an autopsy frequency of 0.001% to 0.30%.<Reference refidx="1"/> In one report, the percentage of cardiac surgeries performed as a  result of cardiac tumors was 0.093%.<Reference refidx="2"/></Para><Para id="_2340">The distribution of cardiac tumors in the fetal and neonatal period is different from that in older patients,  with two-thirds of teratomas occurring during this period of life.<Reference refidx="3"/></Para><Para id="_2128">The most common primary tumors of the heart are benign and include the following:<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/></Para><ItemizedList id="_1508" Style="bullet"><ListItem>Rhabdomyomas.</ListItem><ListItem>Myxomas.</ListItem><ListItem>Teratomas.</ListItem><ListItem>Fibromas.</ListItem></ItemizedList><Para id="_1509">  Other benign tumors include histiocytoid cardiomyopathy tumors, hemangiomas, and neurofibromas (i.e., tumors of the nerves that innervate the muscles).<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/></Para><Para id="_1066">Primary malignant pediatric heart tumors are rare and include the following:<Reference refidx="4"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/></Para><ItemizedList id="_1510" Style="bullet"><ListItem> Malignant teratomas.</ListItem><ListItem>Lymphomas.</ListItem><ListItem>Various sarcomas, including rhabdomyosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, leiomyosarcoma, chondrosarcoma, synovial sarcoma, and infantile fibrosarcoma.</ListItem></ItemizedList><Para id="_1067">Secondary tumors of the heart  include metastatic spread of rhabdomyosarcoma,
other sarcomas, melanoma, leukemia, thymoma, and carcinomas of various sites.<Reference refidx="1"/><Reference refidx="4"/> </Para><ReferenceSection><Citation idx="1" PMID="15811617">Butany J, Nair V, Naseemuddin A, et al.: Cardiac tumours: diagnosis and management. Lancet Oncol 6 (4): 219-28, 2005.</Citation><Citation idx="2" PMID="22735896">Bielefeld KJ, Moller JH: Cardiac tumors in infants and children: study of 120 operated patients. Pediatr Cardiol 34 (1): 125-8, 2013.</Citation><Citation idx="3" PMID="15360117">Isaacs H: Fetal and neonatal cardiac tumors. Pediatr Cardiol 25 (3): 252-73, 2004 May-Jun.</Citation><Citation idx="4" PMID="18402818">Burke A, Virmani R: Pediatric heart tumors. Cardiovasc Pathol 17 (4): 193-8, 2008 Jul-Aug.</Citation><Citation idx="5" PMID="10865004">Becker AE: Primary heart tumors in the pediatric age group: a review of salient pathologic features relevant for clinicians. Pediatr Cardiol 21 (4): 317-23, 2000 Jul-Aug.</Citation><Citation idx="6" PMID="22626745">Padalino MA, Vida VL, Boccuzzo G, et al.: Surgery for primary cardiac tumors in children: early and late results in a multicenter European Congenital Heart Surgeons Association study. Circulation 126 (1): 22-30, 2012.</Citation><Citation idx="7" PMID="12031001" MedlineID="22028356">Elderkin RA, Radford DJ: Primary cardiac tumours in a paediatric population. J Paediatr Child Health 38 (2): 173-7, 2002.</Citation><Citation idx="8" PMID="17331235">Uzun O, Wilson DG, Vujanic GM, et al.: Cardiac tumours in children. Orphanet J Rare Dis 2: 11, 2007.</Citation><Citation idx="9" PMID="21163893">Bruce CJ: Cardiac tumours: diagnosis and management. Heart 97 (2): 151-60, 2011.</Citation><Citation idx="10" PMID="21440163">Kogon B, Shehata B, Katzenstein H, et al.: Primary congenital infantile fibrosarcoma of the heart: the first confirmed case. Ann Thorac Surg 91 (4): 1276-80, 2011.</Citation><Citation idx="11" PMID="23647858">Wang JG, Li NN: Primary cardiac synovial sarcoma. Ann Thorac Surg 95 (6): 2202-9, 2013.</Citation><Citation idx="12" PMID="24701226">Ostrowski S, Marcinkiewicz A, Kośmider A, et al.: Sarcomas of the heart as a difficult interdisciplinary problem. Arch Med Sci 10 (1): 135-48, 2014.</Citation></ReferenceSection></SummarySection><SummarySection id="_1068"><Title>Risk Factors</Title><Para id="_1069">Multiple cardiac tumors noted in the fetal or neonatal period are highly associated with a diagnosis of tuberous sclerosis.<Reference refidx="1"/><Reference refidx="2"/> </Para><Para id="_2341">A retrospective review of 94 patients with cardiac tumors detected by prenatal or neonatal echocardiography showed that 68% of the patients exhibited features of tuberous sclerosis.<Reference refidx="3"/> In another study, 79% of patients (15 of 19) with rhabdomyomas discovered prenatally had tuberous sclerosis, while 96% of those diagnosed postnatally had tuberous sclerosis.  </Para><Para id="_1065">Carney complex is a risk factor for developing myxomas. Carney complex is a rare syndrome characterized by lentigines, cardiac myxomas or other myxoid fibromas, and endocrine abnormalities.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/>

A variant of the <GeneName>PRKAR1A</GeneName> gene is noted in more than 90% of Carney complex cases.<Reference refidx="4"/><Reference refidx="7"/></Para><ReferenceSection><Citation idx="1" PMID="15360117">Isaacs H: Fetal and neonatal cardiac tumors. Pediatr Cardiol 25 (3): 252-73, 2004 May-Jun.</Citation><Citation idx="2" PMID="23151153">Kocabaş A, Ekici F, Cetin Iİ, et al.: Cardiac rhabdomyomas associated with tuberous sclerosis complex in 11 children: presentation to outcome. Pediatr Hematol Oncol 30 (2): 71-9, 2013.</Citation><Citation idx="3" PMID="12914889">Tworetzky W, McElhinney DB, Margossian R, et al.: Association between cardiac tumors and tuberous sclerosis in the fetus and neonate. Am J Cardiol 92 (4): 487-9, 2003.</Citation><Citation idx="4" PMID="17133108">Boikos SA, Stratakis CA: Carney complex: the first 20 years. Curr Opin Oncol 19 (1): 24-9, 2007.</Citation><Citation idx="5">Carney JA, Young WF: Primary pigmented nodular adrenocortical disease and its associated conditions. Endocrinologist  2: 6-21, 1992.</Citation><Citation idx="6" PMID="11549623">Stratakis CA, Kirschner LS, Carney JA: Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 86 (9): 4041-6, 2001.</Citation><Citation idx="7" PMID="17047382">Boikos SA, Stratakis CA: Carney complex: pathology and molecular genetics. Neuroendocrinology 83 (3-4): 189-99, 2006.</Citation></ReferenceSection></SummarySection><SummarySection id="_1070"><Title>Clinical Presentation and Diagnostic Evaluation</Title><Para id="_1071">Patients may be asymptomatic and present with sudden death,<Reference refidx="1"/>[<LOERef href="CDR0000810035" dictionary="NotSet" audience="Health professional">Level of evidence C1</LOERef>] but about two-thirds of patients have symptoms that may include the following:</Para><ItemizedList id="_1270" Style="bullet"><ListItem>Abnormalities of heart rhythm. A single-institution retrospective analysis of 97 children with benign cardiac tumors identified clinically significant arrhythmias in about 25% of the study population. Larger tumors and histological diagnoses of fibromas were associated with a higher risk of cardiovascular death and malignant ventricular arrhythmias.<Reference refidx="2"/></ListItem><ListItem>Enlargement of
the heart.</ListItem><ListItem>Fluid in the pericardial sac.</ListItem><ListItem>Congestive heart failure.</ListItem><ListItem>Syncope.</ListItem><ListItem>Stroke.</ListItem><ListItem>Respiratory distress.<Reference refidx="3"/> 
 </ListItem></ItemizedList><Para id="_1072">Cardiac magnetic resonance imaging using specific sequences can lead to an accurate diagnosis in most patients with cardiac tumors.<Reference refidx="4"/><Reference refidx="5"/> However, a histological diagnosis should remain the standard  in cases where the diagnosis cannot be established by noninvasive methods or if the possibility of malignancy has been considered. Newer techniques such as radiomic technology may be useful in the future management of these children.<Reference refidx="6"/></Para><ReferenceSection><Citation idx="1" PMID="23206573">Neri M, Di Donato S, Maglietta R, et al.: Sudden death as presenting symptom caused by cardiac primary multicentric left ventricle rhabdomyoma, in an 11-month-old baby. An immunohistochemical study. Diagn Pathol 7: 169, 2012.</Citation><Citation idx="2" PMID="39326704">Placidi S, Calcagni G, Lioncino M, et al.: Type and dimensions can predict ventricular arrhythmias and cardiac death in primary benign cardiac tumors in children. Int J Cardiol 418: 132599, 2025.</Citation><Citation idx="3" PMID="22626745">Padalino MA, Vida VL, Boccuzzo G, et al.: Surgery for primary cardiac tumors in children: early and late results in a multicenter European Congenital Heart Surgeons Association study. Circulation 126 (1): 22-30, 2012.</Citation><Citation idx="4" PMID="34419404">Beroukhim RS, Ghelani S, Ashwath R, et al.: Accuracy of Cardiac Magnetic Resonance Imaging in Diagnosing Pediatric Cardiac Masses: A Multicenter Study. JACC Cardiovasc Imaging 15 (8): 1391-1405, 2022.</Citation><Citation idx="5" PMID="21867841">Beroukhim RS, Prakash A, Buechel ER, et al.: Characterization of cardiac tumors in children by cardiovascular magnetic resonance imaging: a multicenter experience. J Am Coll Cardiol 58 (10): 1044-54, 2011.</Citation><Citation idx="6" PMID="36083866">Morin CE, Griffin LM, Beroukhim RS, et al.: Imaging of pediatric cardiac tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. Pediatr Blood Cancer 70 Suppl 4 (Suppl 4): e29955, 2023.</Citation></ReferenceSection></SummarySection><SummarySection id="_1073"><Title>Treatment of Childhood Cardiac Tumors</Title><Para id="_1074">Successful treatment may require surgery, debulking for progressive symptoms, cardiac transplant, and
chemotherapy that is appropriate for the type of cancer.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>; <Reference refidx="4"/>[<LOERef href="CDR0000810035" dictionary="NotSet" audience="Health professional">Level of evidence C1</LOERef>] In one series, 95% of patients were free from cardiac tumor recurrence at 10 years.<Reference refidx="5"/> A meta-analysis of 713 pediatric patients revealed a cumulative, 30-day overall mortality rate of 5.5%, with a rate of 7.5% for patients after surgery. A lower mortality rate was seen in children younger than 1 year.<Reference refidx="6"/></Para><Para id="_2129">Treatment options for  childhood cardiac tumors, according to tumor type or resectability, are as follows:</Para><SummarySection id="_2342"><Title>Rhabdomyomas</Title><Para id="_2343">Most rhabdomyomas, whether diagnosed prenatally or postnatally, will spontaneously regress.<Reference refidx="7"/> However, although some lesions can regress spontaneously, certain practitioners may recommend prophylactic resection to prevent mass-related complications.<Reference refidx="5"/><Reference refidx="8"/><Reference refidx="9"/>; <Reference refidx="10"/>[<LOERef href="CDR0000810037" dictionary="NotSet" audience="Health professional">Level of evidence C2</LOERef>]  </Para><Para id="_2351">Treatment with the mammalian target of rapamycin (mTOR) inhibitors everolimus or sirolimus has been reported to be associated with a decrease in the size of rhabdomyomas in patients with tuberous sclerosis.<Reference refidx="9"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/></Para></SummarySection><SummarySection id="_2344"><Title>Sarcomas</Title><Para id="_2345">Patients with cardiac sarcomas have a poor outcome and can be treated with multimodal therapy. The use of preoperative chemotherapy and/or radiation therapy may be of value in reducing tumor volume before surgery. </Para></SummarySection><SummarySection id="_2346"><Title>Other Tumor Types</Title><Para id="_2347">Complete surgical excision of other lesions offers the best chance for cure. Postoperative complications are seen in about one-third of patients, and postoperative mortality rates are less than 10%.<Reference refidx="5"/><Reference refidx="8"/><Reference refidx="15"/> </Para></SummarySection><SummarySection id="_2348"><Title>Unresectable Tumors</Title><Para id="_2349">Radiation therapy is a rare treatment option for patients with unresectable disease. Radiation therapy is used to prevent progression because it is unlikely to produce full disease resolution.<Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/></Para></SummarySection><ReferenceSection><Citation idx="1" PMID="9344319" MedlineID="98003004">Michler RE, Goldstein DJ: Treatment of cardiac tumors by orthotopic cardiac transplantation. Semin Oncol 24 (5): 534-9, 1997.</Citation><Citation idx="2" PMID="11675188" MedlineID="21531449">Stiller B, Hetzer R, Meyer R, et al.: Primary cardiac tumours: when is surgery necessary? Eur J Cardiothorac Surg 20 (5): 1002-6, 2001.</Citation><Citation idx="3" PMID="18600370">Günther T, Schreiber C, Noebauer C, et al.: Treatment strategies for pediatric patients with primary cardiac and pericardial tumors: a 30-year review. Pediatr Cardiol 29 (6): 1071-6, 2008.</Citation><Citation idx="4" PMID="18980220">Wu KH, Mo XM, Liu YL: Clinical analysis and surgical results of cardiac myxoma in pediatric patients. J Surg Oncol 99 (1): 48-50, 2009.</Citation><Citation idx="5" PMID="22626745">Padalino MA, Vida VL, Boccuzzo G, et al.: Surgery for primary cardiac tumors in children: early and late results in a multicenter European Congenital Heart Surgeons Association study. Circulation 126 (1): 22-30, 2012.</Citation><Citation idx="6" PMID="35113182">Svobodov AA, Glushko LA, Ergashov AY: Surgical Treatment of Primary Cardiac Tumors in Children Systematic Review and Meta-analysis. Pediatr Cardiol 43 (2): 251-266, 2022.</Citation><Citation idx="7" PMID="14615733">Bader RS, Chitayat D, Kelly E, et al.: Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex. J Pediatr 143 (5): 620-4, 2003.</Citation><Citation idx="8" PMID="22735896">Bielefeld KJ, Moller JH: Cardiac tumors in infants and children: study of 120 operated patients. Pediatr Cardiol 34 (1): 125-8, 2013.</Citation><Citation idx="9" PMID="23151153">Kocabaş A, Ekici F, Cetin Iİ, et al.: Cardiac rhabdomyomas associated with tuberous sclerosis complex in 11 children: presentation to outcome. Pediatr Hematol Oncol 30 (2): 71-9, 2013.</Citation><Citation idx="10" PMID="23692835">Kutluk T, Demir HA, Büyükpamukçu M, et al.: Cardiac rhabdomyomas in childhood: six cases from a single institution. Turk J Pediatr 55 (1): 69-73, 2013 Jan-Feb.</Citation><Citation idx="11" PMID="26661560">Choudhry S, Nguyen HH, Anwar S: Rapid resolution of cardiac rhabdomyomas following everolimus therapy. BMJ Case Rep 2015: , 2015.</Citation><Citation idx="12" PMID="29742370">Barnes BT, Procaccini D, Crino J, et al.: Maternal Sirolimus Therapy for Fetal Cardiac Rhabdomyomas. N Engl J Med 378 (19): 1844-1845, 2018.</Citation><Citation idx="13" PMID="33148352">Nir-David Y, Brosilow S, Khoury A: Rapid response of a cardiac rhabdomyoma causing severe right ventricular outflow obstruction to Sirolimus in an infant with negative genetics for Tuberous sclerosis. Cardiol Young 31 (2): 312-314, 2021.</Citation><Citation idx="14" PMID="33631166">Chen XQ, Wang YY, Zhang MN, et al.: Sirolimus Can Increase the Disappearance Rate of Cardiac Rhabdomyomas Associated with Tuberous Sclerosis: A Prospective Cohort and Self-Controlled Case Series Study. J Pediatr 233: 150-155.e4, 2021.</Citation><Citation idx="15" PMID="33517672">Beroukhim RS, Geva T, Del Nido P, et al.: Risk Factors for Left Ventricular Dysfunction Following Surgical Management of Cardiac Fibroma. Circ Cardiovasc Imaging 14 (2): e011748, 2021.</Citation><Citation idx="16" PMID="9726764">Movsas B, Teruya-Feldstein J, Smith J, et al.: Primary cardiac sarcoma: a novel treatment approach. Chest 114 (2): 648-52, 1998.</Citation><Citation idx="17" PMID="18428209">Simpson L, Kumar SK, Okuno SH, et al.: Malignant primary cardiac tumors: review of a single institution experience. Cancer 112 (11): 2440-6, 2008.</Citation><Citation idx="18" PMID="12740300">Mery GM, Reardon MJ, Haas J, et al.: A combined modality approach to recurrent cardiac sarcoma resulting in a prolonged remission: a case report. Chest 123 (5): 1766-8, 2003.</Citation><Citation idx="19" PMID="8873746">Zerkowski HR, Hofmann HS, Gybels I, et al.: Primary sarcoma of pulmonary artery and valve: multimodality treatment by chemotherapy and homograft replacement. J Thorac Cardiovasc Surg 112 (4): 1122-4, 1996.</Citation></ReferenceSection></SummarySection><SummarySection id="_1925"><Title>Treatment Options Under Clinical Evaluation for Childhood Cardiac Tumors</Title><Para id="_1926">Information about National Cancer Institute (NCI)–supported clinical trials can be found on the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">NCI website</ExternalRef>. For information about clinical trials sponsored by other organizations, see the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov website</ExternalRef>.</Para></SummarySection><SummarySection id="_1864"><SectMetaData><SectionType>Unusual Cancers Special Considerations</SectionType></SectMetaData><Title>Special Considerations for the Treatment of Children With Cancer</Title>

<Para id="_1864_md_3">Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.<Reference refidx="1"/>    Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence.  This multidisciplinary team approach incorporates the skills
of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation
to achieve optimal survival and quality of life:</Para>
        <ItemizedList id="_1864_md_4" Style="bullet"><ListItem>Primary care physicians.</ListItem><ListItem>Pediatric surgeons.</ListItem><ListItem>Pathologists.</ListItem><ListItem>Pediatric radiation
oncologists.</ListItem><ListItem>Pediatric medical oncologists and hematologists.</ListItem><ListItem>Ophthalmologists.</ListItem><ListItem> Rehabilitation
specialists.</ListItem><ListItem>Pediatric oncology nurses.</ListItem><ListItem>Social workers.</ListItem><ListItem>Child-life professionals.</ListItem><ListItem>Psychologists.</ListItem><ListItem>Nutritionists.</ListItem></ItemizedList>
 <Para id="_1864_md_5">For specific information about supportive care for children and adolescents with cancer, see the summaries on <ExternalRef xref="https://www.cancer.gov/publications/pdq/information-summaries/supportive-care">Supportive and Palliative Care</ExternalRef>.</Para><Para id="_1864_md_6">The American Academy of Pediatrics has outlined guidelines for
pediatric cancer centers and their role in the treatment of children and adolescents
with cancer.<Reference refidx="2"/>  At
these centers, clinical trials are available for most  types of cancer that occur in children and adolescents, and the opportunity
to participate is offered to most patients and their families.  Clinical
trials for children and adolescents diagnosed with cancer are generally
designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis.  Most of the progress in identifying curative
therapies for childhood cancers has been achieved through clinical trials. 
Information about ongoing clinical trials is available from the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para><Para id="_1864_md_7">Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment.  For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see <SummaryRef href="CDR0000343584" url="/types/childhood-cancers/late-effects-hp-pdq">Late Effects of Treatment for Childhood Cancer</SummaryRef>.</Para>
<Para id="_1864_md_8">Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.<Reference refidx="6"/> The U.S. <ExternalRef xref="https://www.congress.gov/107/plaws/publ280/PLAW-107publ280.pdf">Rare Diseases Act of 2002</ExternalRef> defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.</Para><Para id="_1864_md_9">The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.<Reference refidx="7"/><Reference refidx="8"/> In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:</Para><ItemizedList id="_1864_md_10" Style="bullet"><ListItem>A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included  in the very rare group due to a lack of knowledge and expertise in the management of these tumors.<Reference refidx="9"/></ListItem><ListItem>The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).<Reference refidx="10"/>  These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.<Reference refidx="4"/><Para id="_11"> Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.</Para></ListItem></ItemizedList><Para id="_1864_md_12">These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.</Para><ReferenceSection><Citation idx="1" PMID="20404250">Smith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010.</Citation><Citation idx="2">American Academy of Pediatrics: Standards for pediatric cancer centers. Pediatrics  134 (2): 410-4, 2014. <ExternalRef xref="https://pediatrics.aappublications.org/content/134/2/410">Also available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="3" PMID="24853691">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014.</Citation><Citation idx="4">National Cancer Institute: NCCR*Explorer: An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://NCCRExplorer.ccdi.cancer.gov/">Available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="5">Surveillance Research Program, National Cancer Institute: SEER*Explorer: An interactive website for SEER cancer statistics. 	Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://seer.cancer.gov/statistics-network/explorer/">Available online</ExternalRef>. Last accessed December 30, 2024.</Citation><Citation idx="6" PMID="24488779">Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64 (2): 83-103, 2014 Mar-Apr.</Citation><Citation idx="7" PMID="28687376">Gatta G, Capocaccia R, Botta L, et al.: Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 18 (8): 1022-1039, 2017.</Citation><Citation idx="8" PMID="28542893">DeSantis CE, Kramer JL, Jemal A: The burden of rare cancers in the United States. CA Cancer J Clin 67 (4): 261-272, 2017.</Citation><Citation idx="9" PMID="30785015">Ferrari A, Brecht IB, Gatta G, et al.: Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110: 120-126, 2019.</Citation><Citation idx="10" PMID="20956621">Pappo AS, Krailo M, Chen Z, et al.: Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans. J Clin Oncol 28 (33): 5011-6, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_2130"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (04/03/2025)</Title><Para id="_2131">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</Para><Para id="_2504"><Strong><SummaryRef href="CDR0000799419#_1070" url="/types/cardiac/hp-child-cardiac-treatment-pdq">Clinical Presentation and Diagnostic Evaluation</SummaryRef></Strong></Para><Para id="_2505">Added <SummaryRef href="CDR0000799419#_1270" url="/types/cardiac/hp-child-cardiac-treatment-pdq">text</SummaryRef> to state that a single-institution retrospective analysis of 97 children with benign cardiac tumors identified clinically significant arrhythmias in about 25% of the study population. Larger tumors and histological diagnoses of fibromas were associated with a higher risk of cardiovascular death and malignant ventricular arrhythmias (cited Placidi et al. as reference 2).</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000799419#_AboutThis_1" url="/types/cardiac/hp-child-cardiac-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood cardiac tumors. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Childhood Cardiac Tumors Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Denise Adams, MD (Children's Hospital Boston)</ListItem><ListItem>Karen J. Marcus, MD, FACR (Dana-Farber of Boston Children's Cancer Center and Blood Disorders Harvard Medical School)</ListItem><ListItem>William H. Meyer, MD</ListItem><ListItem>Paul A. Meyers, MD (Memorial Sloan-Kettering Cancer Center)</ListItem><ListItem>Thomas A. Olson, MD (Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta - Egleston Campus)</ListItem><ListItem>Arthur Kim Ritchey, MD (Children's Hospital of Pittsburgh of UPMC)</ListItem><ListItem>Carlos Rodriguez-Galindo, MD (St. Jude Children's Research Hospital)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Cardiac Tumors Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/cardiac/hp-child-cardiac-treatment-pdq">https://www.cancer.gov/types/cardiac/hp-child-cardiac-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 31593384]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateFirstPublished>2019-10-02</DateFirstPublished><DateLastModified>2025-04-03</DateLastModified></Summary>
